On July 27th, ASBM Advisory Board Chair Philip Schneider presented an online Continuing Education (CE) course entitled the “The State of the Biosimilars Market in 2021”. The course was presented in conjunction with Long Island University College of Pharmacy (LIU-Pharmacy) and viewed by more than 150 pharmacists, mostly from the New York area.

The presentation looked at biosimilar market share in the US, Australia, Canada, and the countries of Western Europe and compared the different approaches these countries have used for driving uptake.

While some countries experimented with forced substitution of government-preferred products, those with the most successful biosimilars markets permitted physicians to retain control over prescribing decisions. These countries achieved savings through the increased competition of many products being freely available and reimbursed by payers.

Dr. Schneider also discussed patient and physician concerns with the non-medical switching of patients who are stable on their current therapies; and  how the U.S. interchangeability standard addresses these concerns.

View Dr. Schneider’s presentation here.